Compare JRSH & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JRSH | IMMX |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1M | 82.6M |
| IPO Year | 2018 | 2021 |
| Metric | JRSH | IMMX |
|---|---|---|
| Price | $3.06 | $7.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.00 | ★ $12.00 |
| AVG Volume (30 Days) | 87.2K | ★ 1.3M |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $146,234,005.00 | N/A |
| Revenue This Year | $11.71 | N/A |
| Revenue Next Year | $7.69 | N/A |
| P/E Ratio | $61.47 | ★ N/A |
| Revenue Growth | ★ 12.25 | N/A |
| 52 Week Low | $2.81 | $1.34 |
| 52 Week High | $4.17 | $7.73 |
| Indicator | JRSH | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 79.16 |
| Support Level | $3.02 | $4.50 |
| Resistance Level | $3.14 | $4.48 |
| Average True Range (ATR) | 0.10 | 0.62 |
| MACD | 0.00 | 0.28 |
| Stochastic Oscillator | 20.00 | 83.29 |
Jerash Holdings (US) Inc along with its subsidiaries, is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers, including Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen, which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, and Speedo. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.